High-Purity 2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl]-4-pyrimidinamine: A Key Intermediate for Brigatinib Synthesis
Discover the critical role of this advanced pharmaceutical intermediate in developing next-generation cancer treatments.
Get a Quote & SampleProduct Core Value
![2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl]-4-pyrimidinamine](https://www.nbinno.com/2025/webimg/gemini_688eceecf31f3_1754189548.png)
2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl]-4-pyrimidinamine
This compound serves as a vital building block in the synthesis of Brigatinib, a targeted therapy for specific types of cancer, particularly non-small cell lung cancer (NSCLC) with ALK rearrangements. Its precise chemical structure and high purity ensure the efficacy and safety of the final drug product.
- This high-purity pharmaceutical intermediate is essential for the precise synthesis of Brigatinib, a critical component in cancer therapy.
- Leverage our advanced chemical synthesis capabilities to secure a reliable supply of this ALK inhibitor intermediate for your research and development needs.
- Achieve greater accuracy in your pharmaceutical manufacturing processes with our high-quality 2,5-Dichloro-N-[2-(dimethylphosphinyl)phenyl]-4-pyrimidinamine, ensuring consistent product outcomes.
- Explore the potential of Brigatinib-related intermediates for developing next-generation cancer treatments by utilizing this key chemical compound.
Advantages Offered
Guaranteed Purity for Efficacy
With a minimum purity of 98.0% (HPLC), this intermediate ensures the effectiveness and predictability of Brigatinib in treating ALK-positive NSCLC, contributing to successful cancer drug synthesis.
Streamlined Synthesis Processes
The well-defined synthesis route, starting from readily available precursors, allows for efficient and scalable production, simplifying the overall pharmaceutical manufacturing pathway.
Critical for Targeted Cancer Therapy
As a key ingredient in Brigatinib, this compound directly supports the development and availability of targeted therapies that offer improved outcomes for patients with specific genetic mutations driving their cancer.
Key Applications
Pharmaceutical Synthesis
This compound is a cornerstone in the synthesis of Brigatinib, an advanced pharmaceutical for treating advanced ALK-positive non-small cell lung cancer (NSCLC).
Oncology Research
Researchers utilize this high-quality intermediate to explore new formulations or combinations for cancer therapy, advancing the field of targeted treatments.
Chemical Intermediate Manufacturing
Serves as a vital component in the production chain for specialized chemicals, supporting the broader fine chemical industry.
Drug Discovery and Development
Essential for the early stages of drug discovery, enabling the exploration of novel ALK and ROS1 inhibitors beyond existing therapies.